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Allo-HSCT is a potentially curative treatment for a variety of hematologic diseases, including lymphoid and myeloid malignancies. Before transplantation, patients undergo conditioning with chemotherapy with or without irradiation, which results in severe immunodeficiency that can take months or years to restore, particularly in the T cell compartment 1,2 . This prolonged T cell deficiency predisposes patients to infection and cancer relapse [3] [4] [5] [6] . Strategies that improve T cell reconstitution and recovery of high TCR diversity could therefore greatly reduce transplant-associated morbidity and mortality 7 .
Restoration of TCR diversity after allo-HSCT depends heavily on the thymic generation of new naive T cells [8] [9] [10] . Thymic function, however, diminishes markedly after the onset of puberty and, in the setting of allo-HSCT, is further impaired by conditioning-associated damage and graft-versus-host disease (GVHD) 11, 12 . Thus, it is unclear how well TCR diversity can be restored, particularly in older patients.
Over the past two decades, several strategies have been developed to probe human TCR diversity. One strategy aims to identify the presence of different TCR families by using flow cytometry or PCR to determine the usage of different TCR variable (V) genes 13, 14 .
A second strategy, called CDR3 size spectratyping, aims to determine polyclonality of the repertoire by using fluorescent primers to measure length variation of the CDR3 region within each TCR V family 15, 16 . Spectratyping has been useful in documenting substantial abnormalities in T cell repertoire composition after allo-HSCT [17] [18] [19] . However, as neither of these strategies is able to measure the frequency of individual TCRs, they can only provide an estimate of repertoire complexity. With the advent of deep sequencing technology, it has now become possible to directly measure TCR diversity with high resolution [20] [21] [22] [23] [24] [25] [26] . Here we built on this approach to address two fundamental questions related to T cell reconstitution after allo-HSCT: how TCR diversity recovers over time and as a function of different sources of stem cells 27, 28 .
RESULTS

Strategy and reproducibility of T cell repertoire analysis
T cells typically express only one TCR-β chain, making sequence analysis of TCR-β complementary DNA (cDNA) a useful measure of TCR diversity. To faithfully evaluate the TCR-β repertoire, we made use of 5′ rapid amplification of cDNA ends (RACE) PCR, which allows amplification of all 48 Vβ genes using a single oligonucleotide pair. To test the reproducibility of this approach 29 , we separately amplified two ~8-ml blood samples from a single patient 138 d after T celldepleted (TCD) peripheral-blood stem cell transplantation (TCD patient 1; Supplementary Table 1 ). For comparison, we also amplified two blood samples from each of four healthy donors (healthy donors 1-4). We analyzed all samples by Roche/454 sequencing, using a Phred quality score average of 30 to minimize sequence errors 30 . We found all 48 Vβ genes among the total TCR sequences ( Supplementary Fig. 1) , confirming that our approach covers the entire TCR-β repertoire. Comparison of the two blood samples from TCD patient 1 showed a highly reproducible pattern of Vβ usage, which differed markedly from the Vβ usage in the healthy donors ( Fig. 1a) . This suggested substantial clonal expansions in the repertoire of the patient, which we confirmed by digital CDR3 size spectratype profiles ( Fig. 1b ).
Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation
We then determined the frequency at which each distinct TCR-β chain or TCR-β clonotype was present. In 15,902 reads obtained from both blood samples from TCD patient 1, we detected 1,097 clonotypes, with the most frequent clonotype comprising 11.7% of the reads (Fig. 1c) . In fact, 19 clonotypes were present at frequencies above 1% and together comprised 70.8% of the reads. In contrast, the most abundant clonotype in healthy donors comprised just 2.8% of the reads, and we found on average only three clonotypes at frequencies above 1% (Supplementary Fig. 1 ). To establish the accuracy of the clonotype frequencies, we compared the clonotype distribution of both blood samples from TCD patient 1. Notably, we found that abundant clonotypes in one blood sample had an almost identical frequency in the other blood sample, resulting in a near-perfect correlation of both clonotype distributions (r = 0.98; Fig. 1d ). In healthy donors, we also detected expanded clonotypes with high reproducibility; however, the average correlation between two blood samples from the same individual was lower (r = 0.44; Supplementary Fig. 1) , primarily because fewer clonotypes passed the threshold for physical presence in a second blood sample (8 ml of ~5 l total, or ~0.16%).
To quantify TCR diversity, we used the inverse Simpson's diversity index (1/D s ), which sums the frequency of each clonotype 31 . This index ranges from 1 to  (that is, from no diversity to infinite diversity) and is highest when all clonotypes are equally distributed. To test the usefulness of this index, we sorted naive and memory CD8 + T cells from healthy donor 1 and found a 20-fold higher TCR diversity in the naive T cell compartment ( Supplementary Fig. 2) . Analysis of the repertoire of TCD patient 1 revealed a very low TCR diversity (1/D s = 23), which was more than 100-fold lower than the average diversity of the four healthy donors (1/D s = 2,525; Fig. 1e ). Therefore, at 138 d after transplant, the T cell repertoire of this patient was highly restricted.
To monitor repertoire recovery over time, we measured TCD patient 1 at three additional time points: days 147, 194 and 377 after transplant. To our surprise, TCR Vβ usage was very different at each time point examined ( Fig. 2a) , indicating high variability of the T cell repertoire. To evaluate individual clonotypes, we first determined whether we had reliably measured the clonotype frequencies. On day 147, we again found a near-perfect correlation between the two blood samples from TCD patient 1 (r = 0.99), and the same held true for days 194 and 377 (r = 1 and r = 0.98, respectively; Fig. 2b) . Comparison of the repertoires on days 138 and 147, however, revealed remarkable shifts in clonotype frequencies ( Fig. 2c) . Although some clonotypes were present at roughly similar frequencies on both of these days, several others differed by more than 100-fold, resulting in a low similarity between the T cell repertoires measured just 9 d apart (r = 0.24). Notably, these repertoire shifts coincided with Epstein-Barr virus (EBV) reactivation in the patient, which we first detected on day 145 and which peaked on day 147 ( Supplementary Fig. 3) . We identified the ninth most abundant clonotype on day 147 (TRBV29-1 and CDR3-β CSVGTGGTNEKLFF) as being specific for the HLA-A2-restricted BMLF1 280 epitope from EBV 32 . Although undetectable on days 138 and 194, this clonotype comprised 2.9% of the reads on day 147 and 0.1% of the reads on day 377, highlighting the potential of our method to track antigen-specific clonotypes. Despite the apparent resolution of EBV reactivation by day 158, subsequent blood samples continued to reveal clonotype frequencies fluctuating over orders of magnitude. Thus, the repertoires of two samples on the same day were highly similar (r = 0.99), whereas on different days, they were markedly distinct (r = 0.25; Fig. 2d ). A notable exception was the repertoires on days 138 and 377, which revealed a surprisingly large degree of similarity (r = 0.87; Supplementary Fig. 3 ). Figure 3 T cell repertoire recovery by three different stem cell sources 6 and 12 months after allo-HSCT. Shown are representative clonotype distribution plots of CD4 + and CD8 + T cells obtained at either 6 or 12 months after conventional (Conv) or TCD peripheral-blood stem cell transplantation or DUCB transplantation. Healthy indicates age-matched healthy donors. (a) Clonotype distribution plots of conventional transplant patients 2 (6 months; red) and 3 (12 months; blue). Values in the lower left corners are the TCR diversities. The numbers of reads were 3,379 for CD4 + and 1,985 for CD8 + for conventional transplant patient 2 and 1,954 for CD4 + and 1,515 for CD8 + for conventional transplant patient 3. (b) Clonotype distribution plots of TCD patients 6 (6 months; red) and 10 (12 months; blue). The numbers of reads were 793 for CD4 + and 2,141 for CD8 + for TCD patient 6 and 2,889 for CD4 + and 694 for CD8 + for TCD patient 10. (c) Clonotype distribution plots of DUCB patients 4 (6 months; red) and 6 (12 months; blue). The numbers of reads were 2,312 for CD4 + and 1,138 for CD8 + for DUCB patient 4 and 2,173 for CD4 + and 680 for CD8 + for DUCB patient 6. (d) Clonotype distribution plots of healthy donor 1. The numbers of reads were 2,856 for CD4 + and 800 for CD8 + . (e) CD4 + T cell diversity in the indicated groups. Symbols represent individual subjects, and bars depict the group means. *P = 0.033 (one-way analysis of variance (ANOVA)). (f) CD8 + T cell diversity in the indicated groups. *P = 0.012 (one-way ANOVA). npg umbilical cord blood (DUCB) transplantation (Fig. 3a-c) . As analysis of TCD patient 1 suggested substantially greater TCR diversity in CD4 + compared to CD8 + T cells (Supplementary Fig. 4) , we separately analyzed both T cell compartments in all additional patients, as well as in five healthy donors (Fig. 3d) . After determining the TCR diversity of each individual, we established the following: first, for all stem cell sources as well as in healthy donors, CD4 + T cell diversity was ~50 times higher than CD8 + T cell diversity (1/D s = 4,665 and 299 d apart) . The numbers of reads were 800 on day 0 and 1,120 on day 109 for healthy donor 1, 2,267 on day 0 and 1,508 on day 109 for healthy donor 3 and 917 on day 0 and 1,068 on day 299 for healthy donor 4. (c) Clonotype distribution plots of CD4 + T cells isolated from conventional transplant patient 6 and TCD patient 8, as well as CD8 + T cells isolated from DUCB patient 7. The values in the lower left corners are the TCR diversities. Over 218 d, conventional transplant patient 6 had a 1.6-fold increase in CD4 + T cell count (from 452 to 722 cells µl −1 ) and a 9.7-fold increase in CD4 + T cell diversity. In contrast, over 284 d, TCD patient 8 had no increase in CD4 + T cell count (from 212 to 207 cells µl −1 ) and no increase in CD4 + T cell diversity. Fig. 3e,f) . Second, healthy donors had the highest TCR diversity of CD4 + T cells (1/D s = 15,470), followed by DUCB recipients after 12 months (1/D s = 5,069), DUCB recipients after 6 months (1/D s = 3,745), conventional transplant recipients after 12 months (1/D s = 3,298), TCD recipients after 12 months (1/D s = 1,871), conventional transplant recipients after 6 months (1/D s = 674) and TCD recipients after 6 months (1/D s = 132). Therefore, DUCB recipients had the highest TCR diversity of all patients and had a significantly (28-fold; P = 0.033) more diverse CD4 + T cell repertoire compared to TCD recipients after 6 months. Notably, this increased TCR diversity also correlated with a substantially greater fraction of naive CD4 + T cells in DUCB recipients compared to TCD recipients (Supplementary Fig. 5 ). Although TCD recipients had limited CD4 + T cell diversity after 6 months, this diversity was 14-fold higher after 12 months, reducing the difference compared to DUCB recipients to threefold. Third, DUCB recipients also had the highest TCR diversity in CD8 + T cells of all patients, which was 14-fold higher than TCD recipients after 6 months and 17-fold higher after 12 months, thereby reaching statistical significance (P = 0.012).
Using the above data, we investigated several clinical parameters that could influence T cell repertoire recovery. We found no significant impact of age or donor on TCR diversity (Fig. 4a,b) . Notably, acute GVHD (grade 2 or 3) and prior systemic steroid treatment were associated with higher TCR diversity, suggesting that these variables do not restrict repertoire recovery (Fig. 4c,d) . In contrast, infection with cytomegalovirus or EBV was associated with lower TCR diversity (Fig. 4e) .
Within each stem cell group, we identified patients who had normal T cell counts but very low TCR diversity at 1 year after transplant (Supplementary Fig. 6 ). To investigate repertoire recovery during the second year after transplant, we reanalyzed TCR diversity in three of these patients at 19-21 months. For comparison, we also reanalyzed three healthy donors. We found stability in the CD4 + T cell repertoires of conventional transplant patient 6 and TCD patient 8 and in the CD8 + T cell repertoire of DUCB patient 7 (Fig. 5a) . We found similar stability in the CD8 + T cell repertoires of healthy donors when measured over 109 d, whereas over 299 d, there was somewhat greater divergence ( Fig. 5b) . Despite occasional changes in clonotype frequencies, TCR diversity in the healthy donors was stable (Supplementary Fig. 7) . In conventional transplant patient 6 the frequency of abundant clonotypes substantially decreased over time, resulting in a tenfold higher CD4 + T cell diversity (Fig. 5c) . In contrast, there was no diversification in the other two patients. Together, these data illustrate the potential of our method to identify patients and transplant protocols that are associated with either more or less T cell repertoire recovery.
DISCUSSION
In this study we established a method to reproducibly and accurately measure human TCR diversity. By combining 5′ RACE PCR with deep sequencing, this method assesses the entire TCR-β repertoire using a single oligonucleotide pair, thereby eliminating amplification bias. This contrasts with TCR sequencing methods based on genomic DNA [20] [21] [22] [23] , which use many different oligonucleotides for amplification, making some degree of bias unavoidable. Although 5′ RACE PCR provides a clear advantage, a limitation is that it requires RNA, and thus changes in TCR transcription could skew the frequency of particular clonotypes. Although we used Roche/454 sequencing here, our approach should be readily adaptable to other platforms with greater sequence coverage, which could help identify infrequent TCRs.
We validated our method by measuring T cell repertoire recovery in allo-HSCT recipients, in whom limited TCR diversity is linked to susceptibility to infection and cancer relapse. Although we found significant improvement in TCR diversity over time, there was substantial variability in the rate of recovery between different stem cell sources. Most notably, DUCB recipients had a 28-fold higher CD4 + T cell diversity compared to TCD recipients after 6 months. This is consistent with clinical findings, which have shown that after 6 months, DUCB recipients have a low incidence of infection 33 and have higher CD4 + T cell numbers and a lower rate of leukemia relapse compared to TCD recipients 27, 33, 34 . Although many variables could contribute to this differential repertoire recovery, it can be explained at least partially by the fact that DUCB recipients receive ~7,000-fold more T cells in their graft, and DUCB transplantation is performed without T cell-depleting regimens 33 .
Besides allo-HSCT, this method should be useful in characterizing T cell immunity in other clinical settings of immune deficiency, autoimmunity and tumor immunity. Ultimately, the ability to measure T cell repertoire complexity with great precision should guide the way for new therapeutic approaches aimed at immune regeneration.
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Methods and any associated references are available in the online version of the paper.
